Compare STRS & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRS | CGEN |
|---|---|---|
| Founded | 1992 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.1M | 143.1M |
| IPO Year | N/A | 2000 |
| Metric | STRS | CGEN |
|---|---|---|
| Price | $24.59 | $1.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 14.2K | ★ 397.7K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,912,000.00 | $6,903,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $231.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.10 | $1.13 |
| 52 Week High | $26.30 | $2.66 |
| Indicator | STRS | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 64.56 | 43.67 |
| Support Level | $23.95 | $1.47 |
| Resistance Level | $26.30 | $1.55 |
| Average True Range (ATR) | 0.93 | 0.08 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 72.97 | 16.01 |
Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the acquisition, entitlement, development, management, operation and sale of commercial, multi- and single-family residential real estate properties, located in the Austin Texas area and other select markets in Texas. It operates its business through two segments namely, Real Estate Operations and Leasing Operations. Real Estate Operations segment encompasses activities associated with entitlement, development, and sale of real estate. Leasing Operations segment involves leasing of commercial space at retail and mixed-use properties and residences in multi-family properties that company developed. Majority of revenue is from Real Estate Operations.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.